Document Type

Journal Article

Publication Date

12-2017

Journal

Molecular Genetics and Metabolism Reports

Volume

13

Inclusive Pages

52-54

DOI

10.1016/j.ymgmr.2017.04.001

Abstract

Fibroblast growth factor-21 (FGF21) levels are elevated in patients with primary mitochondrial disorders but have not been studied in patients with inborn errors of metabolism (IEM) known to have secondary mitochondrial dysfunction. We measured plasma FGF21 by ELISA in patients with and without IEM. FGF21 levels were higher in patients with IEM compared to without IEM (370 pg/dL vs. 0–65 pg/dL). Further study of FGF21 as a biomarker in IEM is warranted.

Comments

Reproduced with permission of Elsevier B.V. Molecular Genetics and Metabolism Reports

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Peer Reviewed

1

Open Access

1

Share

COinS